---

The topic of this book is prevention of type 2 diabetes mellitus and cardiovascular disease which are increasing by epidemic proportions all over the world. Metabolic syndrome is well established risk factor for type 2 diabetes mellitus and cardiovascular disease. Hyperinsulinaemia is considered as the earliest stage of development of type 2 diabetes and a core defect unifying the cardiovascular cluster of the metabolic syndrome. Treatment of the metabolic syndrome and hyperinsulinaemia is essential for the prevention of type 2 diabetes and cardiovascular disease. Metformin is a medication of first choice in therapeutic strategy of type 2 diabetes. The book comprises of two research articles representing results of metformin treatment in people at high risk for development of type 2 diabetes mellitus and cardiovascular disease such as those with hyperinsulinaemia, normal glucose tolerance and metabolic syndrome.

---

The author Petya Kamenova- MD,PhD is a chief research assistant and educator of students, trainee doctors, specializing doctors and general practitioners at the Department of Diabetology of Clinical Center of Endocrinology and Gerontology, Medical University Sofia. She is a specialist on internal diseases, endocrinology and diseases of metabolism.

---